Mar 10 2016
ResApp Health Limited, announced today that it has signed a non-binding memorandum of understanding with a leading humanitarian organization and UniQuest (the main commercialization company of The University of Queensland), to enter into a partnership to field test ResApp’s smartphone-based pneumonia diagnostic tool in the developing world.
Pneumonia is a disease that kills more than 950,000 children under five every year, the vast majority in South Asia and sub-Saharan Africa. Many of these deaths are caused by delays in diagnosis due to the lack of high quality medical care in these regions.
ResApp, UniQuest and the humanitarian organization will work together to secure one or more field sites in the developing world. Subject to approval by local human research ethics committees, field sites are expected to be up-and-running in mid-2016.
Dr Tony Keating, CEO and Managing Director of ResApp said:
We are very excited to collaborate with a global leader in the provision of health services throughout the developing world. Not only will we perform a field trial to gather additional clinical evidence, but we will also develop an in-depth understanding of the difficult environments in which their personnel operate and refine our application to suit.
Community vaccination program reduces pneumonia deaths among elderly in Japan